Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HIMSS 2023
  • Opinion
    • Breaking Bias
    • Commentaries
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - AI and Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Finance
March 15, 2016 12:00 AM

Valeant falls short in Q4, slashes guidance for 2016

Associated Press
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    Embattled Valeant Pharmaceuticals fell short of profit expectations in the fourth quarter and slashed its guidance for the current quarter and the full year, citing lower sales across many of its businesses.

    Shares dropped 27% in morning trading Tuesday.

    The Canadian drugmaker is facing a Securities and Exchange Commission investigation and, separately, scrutiny from Congress over its drug pricing. CEO Michael Pearson recently returned to work after two months recovering from severe pneumonia, then delayed the company's quarterly earnings report by two weeks.

    Amid the disruptions, shares have plummeted to less than one-third of their $263.81 high last August — right before Valeant's practice of buying rights to old drugs and jacking up the prices came under congressional scrutiny.

    Investor activist Bill Ackman's hedge fund, Pershing Square Capital Management, which is one of Valeant's biggest shareholders, then began pushing for changes. Earlier this month, Valeant added three directors to its board, including a Pershing Square executive.

    On Tuesday, Valeant Pharmaceuticals International said its still-preliminary results indicate it lost $336.4 million, or 98 cents per share, in the three months ended Dec. 31. Excluding one-time items, earnings were $2.50 per share, far short of per-share earnings of $2.64 that Wall Street expected, according to a survey by Zacks Investment Research.

    Revenue totaled $2.79 billion, which topped analyst projections for $2.76 billion. The company said sales were down in its dermatology, gastrointestinal, ophthalmology, women's health and Western Europe businesses, among others.

    On March 3, Valeant replaced Deb Jorn, the executive vice president in charge of its U.S dermatology and gastrointestinal businesses.

    Valeant, which did not release results from a year earlier for comparison as is typically done, stressed that the results are preliminary as it reviews its relationship with one-time partner, Philidor. The company is now including a line-item in its earnings particularly related to costs of winding down that arrangement.

    "The challenges of the past few months are not yet behind us and our goal for 2016 is to better balance our priorities across all of our constituencies — physicians, patients, employees, payers, debt holders and shareholders," CEO Michael Pearson said in a statement.

    Valeant said Tuesday that it settled a lawsuit over a billing dispute with R&O Pharmacy, with R&O making an unspecified payment to Valeant. Valeant has said that Philidor's pharmacy network includes R&O. Other terms of the settlement remain confidential, and Valeant said it refutes any suggestion of wrongdoing.

    Separately, Valeant said it has struck a deal to distribute Mysimba, a diet pill made by Orexigen Therapeutics Inc. of San Diego, to distribute the drug in central and eastern Europe.

    Valeant, which is based in Laval, Quebec, now anticipates a first-quarter adjusted profit between $1.30 and $1.55 per share on revenue in a range of $2.3 billion to $2.4 billion. Its prior outlook was for an adjusted profit between $2.35 and $2.55 per share on revenue in a range of $2.8 billion to $3.1 billion.

    For 2016, the company now foresees an adjusted profit between $9.50 and $10.50 per share on revenue in a range of $11 billion to $11.2 billion. Its previous forecast was for an adjusted profit between $13.25 and $13.75 per share on revenue in a range of $12.5 billion to $12.7 billion.

    Analysts polled by FactSet expect first-quarter profit of $2.62 per share on revenue of $2.84 billion and a 2016 profit of $13.27 per share on revenue of $12.42 billion.

    Shares of Valeant dropped $18.67, or 27.1%, to $50.38 in morning trading after dropping as low as $49 earlier in the day. Its shares are down 75% since a year ago.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Copy of states hospital costs_WEB_i.jpg
    Mark Cuban-backed study finds price discrepancies in hospital services
    transparency rx
    PBMs form Transparency-Rx to push for drug pricing reform
    Most Popular
    1
    CMS tries luring providers to revamped Medicare ACOs
    2
    Oregon joins other states in setting ratios for nurse staffing
    3
    Blue Shield CA taps Amazon, Mark Cuban, CVS for new PBM model
    4
    A health innovation hub grows in Lake Nona Medical City
    5
    Hospital-at-home providers push for Medicaid coverage
    Sponsored Content
    Daily Finance Newsletter: Sign up to receive daily news and data that has a direct impact on the business and financing of healthcare.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HIMSS 2023
    • Opinion
      • Breaking Bias
      • Commentaries
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - AI and Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing